Agendia Announces Presentation Of Data Highlighting Symphony Suite Of Genomic Tests (MammaPrint, BluePrint, and TargetPrint) At San Antonio Breast Cancer Symposium

New breast cancer research incorporating the Symphony® suite of genomic tests (MammaPrint®, BluePrint® and TargetPrint®) will be presented in 10 scientific posters at the upcoming 2013 San Antonio Breast Cancer Symposium (SABCS), Dec. 10-14.

“These ten studies further demonstrate Agendia’s continued commitment to providing the oncology community and their breast cancer patients with the most comprehensive and validated picture of tumor biology available in the market,” said Neil Barth, M.D., Agendia’s Chief Medical Officer.

Help employers find you! Check out all the jobs and post your resume.